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The time to ANC 500 ranged from 8 to 19 days with a median
of 10 days. The median length of stay was 21 days. Three patients
experienced early treatment-related mortality. With median follow
up of 21 months, 45 patients have relapsed. The ﬁve year disease
free survival (DFS) is 26% and overall survival (OS) is 58%.
Thirty-nine patients (44%) remain alive and disease free. There
was no difference in DFS (P  .82)or OS (p  .55) between those
patients who received 4 cycles of VAD compared to those who
received any other number of VAD cycles. There appears to be no
advantage to giving anything more than 4 cycles of VAD before
proceeding to stem cell transplant.
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Autologous stem cell transplantation (ASCT) for multiple my-
eloma (MM) results in a slow and progressive decline in progres-
sion free survival. Thalidomide is an effective salvage agent in
patients who relapse with MM after ASCT and produces no my-
elosuppression. Therefore, it is an attractive drug for maintenance
post-ASCT. We gave thalidomide to 21 patients after ASCT for
MM. Patients received therapy with VAD chemotherapy until
maximal response (maximum 4 cycles), mobilization with cyclo-
phosphamide 4000 mg/m2 and G-CSF 10 mcg/kg/day and autol-
ogous collection followed by ASCT after high dose chemotherapy
with melphalan 200 mg/m2. The median age was 57; the M/F ratio
was 1.6/1. Thalidomide was started upon recovery of counts but no
earlier than day 30 post-ASCT. The initial dose was 200 mg QD
and it was incremented by 200 mg every 2 weeks to a maximum of
800 mg QD. Patients who reported intolerance to the higher dose
were tapered to the prior highest tolerated dose and maintained on
it. The monoclonal gammopathy was IgG in 20 patients and Ig A
in 1 patient. Eleven patients underwent one ASCT and 10 had
tandem transplants. The highest sustained dose of thalidomide was
800 mg and the median was 200mg. Therapy was given for 85 to
1306 days (median 357). The median time of follow up was 474
days (range 131 to 2842). The median pre-ASCT, pre-thalidomide
and post-thalidomide monoclonal immunoglobulin (Ig) levels were
1320 mg/dl, 1200 mg/dl and 1430 mg/dl respectively. For those
progresing on thalidomide the average increase on Ig level was
49.9%. In the entire cohort, 13 patients responded whereas 8
progressed. Thalidomide in a dose of at least 200 mg QD was well
tolerated as maintenance post-ASCT in all patients. However,
several patients (38%) relapsed while receiving the drug. A ran-
domized placebo controlled study, stratiﬁed by known risks for
relapse post ASCT is warranted to determine whether thalidomide
maintenance delays the progression of myeloma after ASCT.
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Rationale: We posited that the number of cycles of pre-trans-
plant chemotherapies and/or with radiation (RT) directly impacts
both the procedural CD34 cell yield, and in the number of days
of apheresis required to harvest an overall adequate number of CD
34 cells. Methods: A retrospective analysis of 47 charts from
patients over a 2 year period with multiple myeloma was con-
ducted. We analyzed them for: the type and number of cycles of
chemotherapy, age, sex, and prior radiation therapy. Patients were
sorted into those receiving 4-6 cycles of VAD and those receiving
any other therapies in addition to or instead of VAD. Patients
receiving adjuvant RT similarly divided. Median days-to-adequate-
stem-cell-yield was determined. Cell viability of the apheresis
product was correlated with days-to-white-blood-cell engraftment.
Results: Patients who received VAD only required less apheresis
than those receiving other therapies (median 1 vs. 2 days, p 
0.015). There was no data to suggest that age or sex correlated with
the duration of apheresis. There was no correlation between cell
viability and days-to-white-blood-cell engraftment. Patients re-
ceiving RT in addition to VAD required a median of 1 day of
apheresis. A single patient receiving additional chemotherapy
along with radiation required 4 days of apheresis. Conclusion:
Patients receiving 4-6 cycles of VAD alone had faster adequate
apheresis yields compared with those receiving additional or other
regimens. Radiation did not appear to have an effect on patient’s
CD34 yield who also received VAD as therapy. Further studies
should be pursued to determine the effects of other adjuvant
chemotherapies to VAD, and in patients receiving radiation, in
predicting time to CD34 apheresis yield.
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Patients (pts) with progressive HD following autologous HCT
have limited treatment options and poor prognosis. We evaluated
the utility of nonmyeloablative conditioning and allogeneic HCT
for pts ineligible for high dose conventional allogeneic HCT due
to age and/or comorbidities. Between December 1998 and Octo-
ber 2002, 27 pts (18 MRD, 9 URD) received 2 Gy total body
irradiation alone (n  7 MRD) or with 90 mg/m2 ﬂudarabine (n 
11 MRD, n  9 URD), G-CSF mobilized peripheral blood HCT
and postgrafting immunosuppression with mycophenolate mofetil
and cyclosporine. Median age was 37 (range 21-65) years. Pts were
heavily pretreated and had advanced disease with a median number
of prior regimens of 5 (range 2-9). Most pts had prior radiation
therapy (25/27) and prior high dose autologous HCT (24/27).
Median time between autologous HCT and salvage therapy was 8
(range 2-73) months. Median time between autologous HCT and
allogeneic HCT was 16 (range 2-78) months. At allogeneic HCT,
5 pts were in complete remission (CR), 11 in partial remission
(PR), 4 had relapsed disease and 7 had refractory disease. All pts
engrafted and there were no graft rejections. The overall incidence
of acute Grade II, III, and IV GVHD was 33%, 15%, and 4%
respectively. Incidence of chronic extensive GVHD was 55% at 1
year. The overall response rate, deﬁned as those pts with measur-
able disease prior to transplant who achieved a CR or PR after
allogeneic HCT was 55%. Currently, 9 of 27 pts are alive; 6 are in
CR and 3 have relapsed or have progressive disease (PD), with a
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VAD only (n  25) 1 RT  VAD
(n  5)
1
Other (n  22) 2 RT  other
chemo (n  1)
4
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